Depressive symptoms and single nucleotide polymorphisms predict clinical recurrence of inflammatory bowel disease

Competing Interest Statement

S.B.U.J., B.M.L., B.A., N.K. and S.B. have nothing to disclose. R.v.K. has served at an advisory board of Vifor AG, Switzerland unrelated to this work. L.B. reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap, Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma. TG has consulting contracts with Sanofi-Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis. P.S. reports consultant fees from Pfizer, Takeda and Janssen-Cilag. G.R. has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; G.R. has received speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller; G.R. has received educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller. M.C.S. has received consultant and/or speaker fees from Abbvie, Ferring, MSD, Janssen, Pfizer, Takeda, UCB. B.M. has served at an advisory board for Gilead and Novigenix. He has received speaking fees from Vifor, MSD and Takeda and traveling fees from Vifor, Novartis, MSD and Takeda. BM has received a research grant from MSD unrelated to this work.

Funding Statement

This work was supported by the Swiss National Science Foundation (SNSF), [grant number 33CS30-148422 to G.R.].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional review board approval No. EK-1316, approved on February 5, 2007 and KEK Zurich, March 9, 2020; BASEC 2018-02068. Analysis of patient data for this study was approved by the scientific board of SIBDCS.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes